Holen Sie sich die Stockscreener-App
0.8567
3.90%
-0.0348
Vorhandelsmarkt:
.85
-0.0067
-0.78%
Lexaria Bioscience Corp Aktie (LEXX) Neueste Nachrichten
Earnings visualization tools for Lexaria Bioscience Corp. Equity Warrant2025 Valuation Update & Safe Capital Growth Tips - newser.com
Can trapped investors hope for a rebound in Lexaria Bioscience Corp. Equity WarrantTrade Risk Assessment & Precise Trade Entry Recommendations - newser.com
Will Lexaria Bioscience Corp. Equity Warrant outperform the marketBull Run & Real-Time Volume Spike Alerts - newser.com
Can Lexaria Bioscience Corp. hit a new high this monthMarket Risk Analysis & Smart Allocation Stock Reports - newser.com
Lexaria expands pharmaceutical outreach with new advisory firm By Investing.com - Investing.com Nigeria
Lexaria Bioscience Corp. Provides Strategic Update - NewMediaWire
Lexaria Bioscience Expands Strategic Outreach and Secures New Patents - TipRanks
Lexaria (LEXX) Expands R&D Efforts with Enhanced Funding and New Partnerships - GuruFocus
Lexaria expands pharmaceutical outreach with new advisory firm - Investing.com India
$4.0M Financing backs Lexaria's global BD push; 4 new patents bolster DehydraTECH R&D into 2026 - Stock Titan
Can trapped investors hope for a rebound in Lexaria Bioscience Corp.2025 Major Catalysts & Community Verified Swing Trade Signals - newser.com
Historical volatility pattern of Lexaria Bioscience Corp. visualized2025 Institutional Moves & Fast Momentum Stock Entry Tips - newser.com
Custom watchlist performance reports with Lexaria Bioscience Corp.2025 Major Catalysts & Pattern Based Trade Signal System - newser.com
News impact scoring models applied to Lexaria Bioscience Corp. Equity WarrantMarket Sentiment Report & Real-Time Volume Analysis - newser.com
Can swing trading help recover from Lexaria Bioscience Corp. Equity Warrant losses2025 Key Lessons & Weekly Top Gainers Alerts - newser.com
Lexaria Bioscience Corp Stock Analysis and ForecastAutomated Trading Signals & Explosive Capital Growth - earlytimes.in
Will Lexaria Bioscience Corp. see short term momentumMarket Sentiment Report & Fast Entry High Yield Stock Tips - newser.com
Lexaria Bioscience Corp. Equity Warrant stock daily chart insightsWeekly Risk Report & High Conviction Trade Alerts - newser.com
Real time social sentiment graph for Lexaria Bioscience Corp.Quarterly Trade Review & Technical Pattern Based Buy Signals - newser.com
Smart tools for monitoring Lexaria Bioscience Corp.’s price actionWeekly Market Outlook & Weekly Stock Performance Updates - newser.com
Can Lexaria Bioscience Corp. Equity Warrant stock deliver surprise earnings beatCPI Data & Fast Moving Trade Plans - newser.com
When is the best time to exit Lexaria Bioscience Corp.Entry Point & Community Verified Trade Signals - newser.com
Is Lexaria Bioscience Corp. stock reversal real or fakeAnalyst Downgrade & Reliable Price Action Trade Plans - newser.com
What drives Lexaria Bioscience Corp stock priceFundamental Stock Analysis & High Yield Trading Plans - earlytimes.in
Lexaria Bioscience Corp. Equity Warrant stock trendline breakdownWeekly Stock Summary & Accurate Buy Signal Alerts - newser.com
What’s next for Lexaria Bioscience Corp. Equity Warrant stock price2025 Price Action Summary & Breakout Confirmation Alerts - newser.com
Chart based exit strategy for Lexaria Bioscience Corp. Equity WarrantJuly 2025 Momentum & Free High Return Stock Watch Alerts - newser.com
Will earnings trigger a reversal in Lexaria Bioscience Corp.2025 Stock Rankings & Reliable Trade Execution Plans - newser.com
LEXX: Biodistribution Study Results - Yahoo Finance
Lexaria Bioscience announces ~$4M registered direct offering of shares - MSN
Lexaria Bioscience Ends Capital on Demand Agreement - MSN
Lexaria Bioscience (NASDAQ:LEXX) Trading Down 6.4% – What’s Next? - Defense World
Lexaria Bioscience Secures $4 Million in Capital Funding to Advance 2026 Research Initiatives - citybuzz
Lexaria Bioscience Secures $4 Million for R&D Expansion - TipRanks
Lexaria Bioscience enters securities purchase agreement with investorsSEC filing - TradingView
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain - StreetInsider
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Investing News Network
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):